08/22/2024
7:36 PM | Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/31/2024
6:46 AM | Takeda Pharmaceutical (Filed by)
Xilio Therapeutics, Inc. (Subject)
| Form SC 13G/A | |
07/31/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2024
6:12 AM | Amakawa Akiko (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:13 AM | Plump Andrew Stewart (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:13 AM | Takeda Pharmaceutical (Subject)
Weber Christophe Pierre (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:14 AM | Shannon Elaine Mary (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
07/10/2024
6:15 AM | Ricci Gabriele (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:15 AM | Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:16 AM | Kim Julie So-Young (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:16 AM | Duprey Lauren Rusckowski (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:17 AM | Pignagnoli Agosti Marcello (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:17 AM | Sequeira Ramona (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:18 AM | Bitetti Teresa Marie (Reporting)
Takeda Pharmaceutical (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
6:19 AM | Takeda Pharmaceutical (Subject)
Wozniewski Thomas Otto Claus (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/09/2024
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/05/2024
10:28 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/02/2024
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/01/2024
5:33 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2024
7:24 AM | Takeda Pharmaceutical (Subject)
| Form FWP | |
06/28/2024
7:25 AM | Takeda Pharmaceutical (Filer)
| Form 424B2
Transaction specifc information for a delayed shelf offering | |
06/27/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 424B5 | |
06/26/2024
7:26 AM | Takeda Pharmaceutical (Filer)
| Form F-3ASR | |
06/26/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/26/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/26/2024
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
06/17/2024
5:46 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/11/2024
5:23 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/10/2024
5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/07/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/07/2024
5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/03/2024
5:45 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/03/2024
5:26 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:24 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024
5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/21/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
The death of Nvidia? (Ad) Today, I’m warning of another looming catastrophe.
Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out.
You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy...
There's also no escaping that The Big AI Die-Up is coming. So go here now to read my new report The Big AI Die-Up… while you still can. |
05/09/2024
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024
5:08 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/25/2024
5:04 AM | Takeda Pharmaceutical (Filer)
| Form SD
Specialized Disclosure Report | |
04/19/2024
5:12 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/15/2024
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/10/2024
5:10 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
04/01/2024
5:15 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
03/27/2024
5:34 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/09/2024
5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/06/2024
8:36 AM | BlackRock Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/05/2024
5:24 AM | Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/02/2024
5:16 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024
5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024
5:06 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/25/2024
5:13 AM | Phathom Pharmaceuticals, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:11 AM | Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
01/19/2024
5:03 AM | Equillium, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
| Form SC 13G | |
01/16/2024
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/14/2023
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/30/2023
5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/13/2023
5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2023
5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023
5:22 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023
5:21 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023
5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/02/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/28/2023
5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/11/2023
5:50 AM | Takeda Pharmaceutical (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
